Results 91 to 100 of about 96,485 (242)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

Acta Dermato-Venereologica, 2019
Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative to other ...
Luís Puig, Martin Dossenbach, Lovisa Berggren, Anders Ljungberg, Claus Zachariae   +4 more
doaj   +1 more source

Efficacy and Safety of Oral Icotrokinra in Moderate‐to‐Severe Plaque Psoriasis: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

International Journal of Dermatology, EarlyView.
Meta‐analysis of randomized controlled trials demonstrates that oral icotrokinra significantly improves PASI responses in patients with moderate‐to‐severe plaque psoriasis, with early clinical benefit and a placebo‐comparable safety profile, supported by trial sequential analysis confirming robust and sufficient evidence.
Alhasan Altayf, Munder Lateiresh, Lutfiyah Marwan, Mohamed Yaseen Alfeetouri, Yassine Zouaoui, Muhammed Elhadi   +5 more
wiley   +1 more source

Clinical efficacy and quality of life under micronutrients in combination with methotrexate therapy in chronic plaque of psoriatic patients

Dermatologica Sinica, 2017
Background/objectives: Psoriasis is a common dermatologic disorder, with fluctuating response to treatments. We aimed to investigate the efficacy of methotrexate (MTX) plus micronutrient supplement (MM) compare to MTX only on Psoriasis Area and Severity ...
Hadis Yousefzadeh, Farahzad Jabbari Azad, Mahnaz Banihashemi, Maryam Rastin, Mahmoud Mahmoudi   +4 more
doaj   +1 more source

Towards bounded wait-free PASIS

, 2007
The PASIS read/write protocol implements a Byzantine fault-tolerant erasure-coded atomic register. The prototype PASIS storage system implementation provides excellent best-case performance. Writes require two round trips and contention- and failure-free reads require one.
Abd-El-Malek, Michael, Ganger, Gregory R., Goodson, Garth R., Reiter, Michael K., Wylie, Jay J.   +4 more
openaire   +3 more sources

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weight‐loss interventions were associated with clinically and statistically significant improvements in psoriasis severity (PASI and PASI 75) and quality of life (DLQI). These findings support the role of weight‐loss interventions as effective adjuncts to medical therapy and their integration into holistic psoriasis care.
Sarah Morrow, Poppy Hawkins, Christopher E. M. Griffiths, Thanasis G. Tektonidis, Eli Harriss, Jadine Scragg, Susan Jebb   +6 more
wiley   +1 more source

The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review

Psoriasis: Targets and Therapy
Alim Osman, Alexandra Nigro, Amanda Chen Taylor, Ryan Saal, Ana Ormaza Vera, Clinton Enos Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USACorrespondence: Alim Osman, Department of Dermatology, Eastern Virginia Medical School ...
Osman A, Nigro A, Taylor AC, Saal R, Ormaza Vera A, Enos C   +5 more
doaj  

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr, Ohn A. Chow, Mai Anh Nguyen, Laurent Perrin, Fabienne Schumacher, Frank‐Dietrich Wagner, Caroline Dreis, Amel Lahmar, Markus Kohlmann, Maria Wiekowski, Tiago R. Matos   +10 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Efficacy and safety of secukinumab for moderate to severe plaque psoriasis in children: A report of 10 cases

Pifu-xingbing zhenliaoxue zazhi
Objective To study the efficacy and safety of secukinumab in the treatment of moderate and severe plaque psoriasis in children. Methods A total of 10 children with psoriasis were enrolled at Yongcheng Central Hospital from November 2021 to November 2022.
FU Tao, ZHU Liang, GAO Yonglei, XIE Fang, FAN Menghong, WANG Kun, XIA Ke, CHEN Tao, LIU Chunxi, JIANG Dou   +9 more
doaj   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source